Peptide ligand for target protein

* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.

As a leading service provider in drug discovery and development, BOC Sciences is fully qualified and committed to providing one-stop PROTAC^® development, which has become a promising strategy in the field of small molecular drug discovery. With a comprehensive and advanced platform, we provide Peptide Ligand Design for Target Protein to customers around the world to meet new drug discovery goals.

Introduction

PROTAC is a heterobifunctional molecule, which consists of the following components: ligands that bind POI; ligands that recruit E3 ligases; and intermediate Linker that connects two ligands. Among them, the ligands binding to POI can be peptides or small molecules. Compared with small molecule and protein therapy, peptides have several attractive features, such as high structural compatibility with target proteins, the ability to destroy protein-protein interfaces, and small size. The effective design of high affinity peptide ligands through reasonable methods has always been a major obstacle to the development of this potential drug category.

Application

Peptide ligands have the characteristics of low molecular weight, easy synthesis, good safety, high surface density, and easier to be engineered at the molecular level. Although the affinity between protein and ligand does not represent the degradation efficiency of PROTAC, using mature target proteins and tool compounds, it has been found that the formation and stability of POI ubiquitin-ternary complex are very important for effective degradation.

Our Advantages

• Comprehensive ligand design services
• Industry-standard software and hardware
• Highly experienced scientists
• The advanced ligand design and synthesis platform
• Highly reliable and reproducible result
• Data analysis, detailed report with results and discussion
• Quality one-stop service

Workflow of Ligand Design Services

References:

1. Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., ... & Crews, C. M. (2018). Lessons in Protac design from selective degradation with a promiscuous warhead. Cell chemical biology, 25(1), 78-87.
2. Zou, Y., Ma, D., & Wang, Y. (2019). The Protac technology in drug development. Cell biochemistry and function, 37(1), 21-30.

* PROTAC^® is a registered trademark of Arvinas Operations, Inc., and is used under license.